Targeting androgen receptor for prostate cancer therapy: From small molecules to PROTACs
Published 2022 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Targeting androgen receptor for prostate cancer therapy: From small molecules to PROTACs
Authors
Keywords
-
Journal
BIOORGANIC CHEMISTRY
Volume 128, Issue -, Pages 106089
Publisher
Elsevier BV
Online
2022-08-11
DOI
10.1016/j.bioorg.2022.106089
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Overview of the development of selective androgen receptor modulators (SARMs) as pharmacological treatment for osteoporosis (1998–2021)
- (2022) Youquan Xie et al. EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY
- Targeted protein degradation: Emerging concepts and protein state-specific targeting principles
- (2022) Andrew J. Tao et al. CURRENT OPINION IN CHEMICAL BIOLOGY
- An Overview of Next-Generation Androgen Receptor-Targeted Therapeutics in Development for the Treatment of Prostate Cancer
- (2021) Michael L. Mohler et al. INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
- Development of Novel Inhibitors Targeting the D-Box of the DNA Binding Domain of Androgen Receptor
- (2021) Mariia Radaeva et al. INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
- Discovery of A031 as effective proteolysis targeting chimera (PROTAC) androgen receptor (AR) degrader for the treatment of prostate cancer
- (2021) Linrong Chen et al. EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY
- DCAF11 Supports Targeted Protein Degradation by Electrophilic Proteolysis-Targeting Chimeras
- (2021) Xiaoyu Zhang et al. JOURNAL OF THE AMERICAN CHEMICAL SOCIETY
- Chemical Degradation of Androgen Receptor (AR) Using Bicalutamide Analog–Thalidomide PROTACs
- (2021) Ga Yeong Kim et al. MOLECULES
- Targeted protein degraders crowd into the clinic
- (2021) Asher Mullard NATURE REVIEWS DRUG DISCOVERY
- Resistance to second-generation androgen receptor antagonists in prostate cancer
- (2021) Keith T. Schmidt et al. Nature Reviews Urology
- Designed, synthesized and biological evaluation of proteolysis targeting chimeras (PROTACs) as AR degraders for prostate cancer treatment
- (2021) Jian-Jia Liang et al. BIOORGANIC & MEDICINAL CHEMISTRY
- Discovery of ARD-2585 as an Exceptionally Potent and Orally Active PROTAC Degrader of Androgen Receptor for the Treatment of Advanced Prostate Cancer
- (2021) Weiguo Xiang et al. JOURNAL OF MEDICINAL CHEMISTRY
- Exploration and Biological Evaluation of Basic Heteromonocyclic Propanamide Derivatives as SARDs for the Treatment of Enzalutamide-Resistant Prostate Cancer
- (2021) Yali He et al. JOURNAL OF MEDICINAL CHEMISTRY
- Strategies toward Discovery of Potent and Orally Bioavailable Proteolysis Targeting Chimera Degraders of Androgen Receptor for the Treatment of Prostate Cancer
- (2021) Xin Han et al. JOURNAL OF MEDICINAL CHEMISTRY
- Development of an Androgen Receptor Inhibitor Targeting the N-Terminal Domain of Androgen Receptor for Treatment of Castration Resistant Prostate Cancer
- (2021) Fuqiang Ban et al. Cancers
- Design, synthesis, and biological evaluation of phenyl thiazole-based AR-V7 degraders
- (2021) Archana Bhumireddy et al. BIOORGANIC & MEDICINAL CHEMISTRY LETTERS
- Selective androgen receptor modulators: the future of androgen therapy?
- (2020) Andrew R. Christiansen et al. Translational Andrology and Urology
- Androgen sensitivity gateway to COVID ‐19 disease severity
- (2020) Carlos Gustavo Wambier et al. DRUG DEVELOPMENT RESEARCH
- Preclinical profile and phase I clinical trial of a novel androgen receptor antagonist GT0918 in castration-resistant prostate cancer
- (2020) Tie Zhou et al. EUROPEAN JOURNAL OF CANCER
- Combination therapy with androgen receptor N‐terminal domain antagonist EPI‐7170 and enzalutamide yields synergistic activity in AR‐V7‐positive prostate cancer
- (2020) Yukiyoshi Hirayama et al. Molecular Oncology
- Pyrazol-1-yl-propanamides as SARD and Pan-Antagonists for the Treatment of Enzalutamide-Resistant Prostate Cancer
- (2020) Yali He et al. JOURNAL OF MEDICINAL CHEMISTRY
- A highly potent PROTAC androgen receptor (AR) degrader ARD-61 effectively inhibits AR-positive breast cancer cell growth in vitro and tumor growth in vivo
- (2020) Lijie Zhao et al. NEOPLASIA
- Androgen Signaling Regulates SARS-CoV-2 Receptor Levels and Is Associated with Severe COVID-19 Symptoms in Men
- (2020) Ryan M. Samuel et al. Cell Stem Cell
- Design and characterization of cereblon-mediated androgen receptor proteolysis-targeting chimeras
- (2020) Akshay D. Takwale et al. EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY
- Bioactive Steroids from the Red Sea Soft Coral Sinularia polydactyla
- (2020) Mohamed A. Tammam et al. Marine Drugs
- Effects of MTX-23, a Novel PROTAC of Androgen Receptor Splice Variant-7 and Androgen Receptor, on CRPC resistant to Second-Line Antiandrogen Therapy
- (2020) Geun Taek Lee et al. MOLECULAR CANCER THERAPEUTICS
- Targeting transcriptional regulation of SARS-CoV-2 entry factors ACE2 and TMPRSS2
- (2020) Yuanyuan Qiao et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Discovery of ARD-69 as a Highly Potent Proteolysis Targeting Chimera (PROTAC) Degrader of Androgen Receptor (AR) for the Treatment of Prostate Cancer
- (2019) Xin Han et al. JOURNAL OF MEDICINAL CHEMISTRY
- Design and synthesis of novel steroidal imidazoles as dual inhibitors of AR/CYP17 for the treatment of prostate cancer
- (2019) Qiangqiang Hou et al. STEROIDS
- Tetrahydropyrazolo[1,5-a]pyridine-fused steroids and their in vitro biological evaluation in prostate cancer
- (2019) Radek Jorda et al. EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY
- Orally Bioavailable Androgen Receptor Degrader, Potential Next-Generation Therapeutic for Enzalutamide-Resistant Prostate Cancer
- (2019) Suriyan Ponnusamy et al. CLINICAL CANCER RESEARCH
- Synthesis of novel galeterone derivatives and evaluation of their in vitro activity against prostate cancer cell lines
- (2019) Radek Jorda et al. EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY
- Galeterone and The Next Generation Galeterone Analogs, VNPP414 and VNPP433-3β Exert Potent Therapeutic Effects in Castration-/Drug-Resistant Prostate Cancer Preclinical Models In Vitro and In Vivo
- (2019) Andrew K. Kwegyir-Afful et al. Cancers
- Discovery of Highly Potent and Efficient PROTAC Degraders of Androgen Receptor (AR) by Employing Weak Binding Affinity VHL E3 Ligase Ligands
- (2019) Xin Han et al. JOURNAL OF MEDICINAL CHEMISTRY
- Discovery and development of ODM-204: A Novel nonsteroidal compound for the treatment of castration-resistant prostate cancer by blocking the androgen receptor and inhibiting CYP17A1
- (2018) Riikka Oksala et al. JOURNAL OF STEROID BIOCHEMISTRY AND MOLECULAR BIOLOGY
- Androgen Receptor–Targeted Treatments for Prostate Cancer: 35 Years’ Progress with Antiandrogens
- (2018) E. David Crawford et al. JOURNAL OF UROLOGY
- Development of selective androgen receptor modulators (SARMs)
- (2018) Ramesh Narayanan et al. MOLECULAR AND CELLULAR ENDOCRINOLOGY
- Selectively targeting the dimerization interface of human androgen receptor with small-molecules to treat castration-resistant prostate cancer
- (2018) Kush Dalal et al. CANCER LETTERS
- Perspectives on the current and emerging chemical androgen receptor antagonists for the treatment of prostate cancer
- (2018) Athanasios E. Dellis et al. EXPERT OPINION ON PHARMACOTHERAPY
- New Generation of Selective Androgen Receptor Degraders: Our Initial Design, Synthesis, and Biological Evaluation of New Compounds with Enzalutamide-Resistant Prostate Cancer Activity
- (2018) Dong-Jin Hwang et al. JOURNAL OF MEDICINAL CHEMISTRY
- Molecules targeting the androgen receptor (AR) signaling axis beyond the AR-Ligand binding domain
- (2018) N. G. R. Dayan Elshan et al. MEDICINAL RESEARCH REVIEWS
- A magic drug target: Androgen receptor
- (2018) Dan Li et al. MEDICINAL RESEARCH REVIEWS
- Darolutamide (ODM-201) for the treatment of prostate cancer
- (2017) Neal D. Shore EXPERT OPINION ON PHARMACOTHERAPY
- Development of Protein Degradation Inducers of Androgen Receptor by Conjugation of Androgen Receptor Ligands and Inhibitor of Apoptosis Protein Ligands
- (2017) Norihito Shibata et al. JOURNAL OF MEDICINAL CHEMISTRY
- Targeting Androgen Receptor Activation Function-1 with EPI to Overcome Resistance Mechanisms in Castration-Resistant Prostate Cancer
- (2016) Y. C. Yang et al. CLINICAL CANCER RESEARCH
- Sintokamide A Is a Novel Antagonist of Androgen Receptor That Uniquely Binds Activation Function-1 in Its Amino-terminal Domain
- (2016) Carmen A. Banuelos et al. JOURNAL OF BIOLOGICAL CHEMISTRY
- Screening of synthetic and natural product databases: Identification of novel androgens and antiandrogens
- (2015) Claudia Bobach et al. EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY
- Discovery and Development of Galeterone (TOK-001 or VN/124-1) for the Treatment of All Stages of Prostate Cancer
- (2015) Vincent C. O. Njar et al. JOURNAL OF MEDICINAL CHEMISTRY
- Conversion of abiraterone to D4A drives anti-tumour activity in prostate cancer
- (2015) Zhenfei Li et al. NATURE
- Discovery of ODM-201, a new-generation androgen receptor inhibitor targeting resistance mechanisms to androgen signaling-directed prostate cancer therapies
- (2015) Anu-Maarit Moilanen et al. Scientific Reports
- Androgen receptor: structure, role in prostate cancer and drug discovery
- (2014) MH Eileen Tan et al. ACTA PHARMACOLOGICA SINICA
- Identification of a Potent Antiandrogen that Targets the BF3 Site of the Androgen Receptor and Inhibits Enzalutamide-Resistant Prostate Cancer
- (2014) Ravi S.N. Munuganti et al. CHEMISTRY & BIOLOGY
- Discovery of Small-Molecule Inhibitors Selectively Targeting the DNA-Binding Domain of the Human Androgen Receptor
- (2014) Huifang Li et al. JOURNAL OF MEDICINAL CHEMISTRY
- Discovery of 1H-Indole-2-carboxamides as Novel Inhibitors of the Androgen Receptor Binding Function 3 (BF3)
- (2014) Fuqiang Ban et al. JOURNAL OF MEDICINAL CHEMISTRY
- Characterization of Niphatenones that Inhibit Androgen Receptor N-Terminal Domain
- (2014) Carmen A. Banuelos et al. PLoS One
- The Androgen-Regulated Protease TMPRSS2 Activates a Proteolytic Cascade Involving Components of the Tumor Microenvironment and Promotes Prostate Cancer Metastasis
- (2014) J. M. Lucas et al. Cancer Discovery
- Ligand-Independent and Tissue-Selective Androgen Receptor Inhibition by Pyrvinium
- (2013) Minyoung Lim et al. ACS Chemical Biology
- Glucocorticoid Receptor Confers Resistance to Antiandrogens by Bypassing Androgen Receptor Blockade
- (2013) Vivek K. Arora et al. CELL
- Abiraterone Acetate in Combination with Prednisone for the Treatment of Patients with Metastatic Castration-Resistant Prostate Cancer: U.S. Food and Drug Administration Drug Approval Summary
- (2013) P. G. Kluetz et al. CLINICAL CANCER RESEARCH
- Identification of Novel Androgen Receptor Antagonists Using Structure- and Ligand-Based Methods
- (2013) Huifang Li et al. Journal of Chemical Information and Modeling
- An androgen receptor N-terminal domain antagonist for treating prostate cancer
- (2013) Jae-Kyung Myung et al. JOURNAL OF CLINICAL INVESTIGATION
- Targeting the Binding Function 3 (BF3) Site of the Androgen Receptor Through Virtual Screening. 2. Development of 2-((2-phenoxyethyl) thio)-1H-benzimidazole Derivatives
- (2013) Ravi Shashi Nayana Munuganti et al. JOURNAL OF MEDICINAL CHEMISTRY
- Systematic Structure Modifications of Multitarget Prostate Cancer Drug Candidate Galeterone To Produce Novel Androgen Receptor Down-Regulating Agents as an Approach to Treatment of Advanced Prostate Cancer
- (2013) Puranik Purushottamachar et al. JOURNAL OF MEDICINAL CHEMISTRY
- Characterization of a New Class of Androgen Receptor Antagonists with Potential Therapeutic Application in Advanced Prostate Cancer
- (2013) Huifang Li et al. MOLECULAR CANCER THERAPEUTICS
- An F876L Mutation in Androgen Receptor Confers Genetic and Phenotypic Resistance to MDV3100 (Enzalutamide)
- (2013) M. Korpal et al. Cancer Discovery
- A Clinically Relevant Androgen Receptor Mutation Confers Resistance to Second-Generation Antiandrogens Enzalutamide and ARN-509
- (2013) J. D. Joseph et al. Cancer Discovery
- ARN-509: A Novel Antiandrogen for Prostate Cancer Treatment
- (2012) N. J. Clegg et al. CANCER RESEARCH
- Interactions of Abiraterone, Eplerenone, and Prednisolone with Wild-type and Mutant Androgen Receptor: A Rationale for Increasing Abiraterone Exposure or Combining with MDV3100
- (2012) J. Richards et al. CANCER RESEARCH
- Steroid derivatives as pure antagonists of the androgen receptor
- (2012) Sylvain Gauthier et al. JOURNAL OF STEROID BIOCHEMISTRY AND MOLECULAR BIOLOGY
- Design, synthesis and biological evaluation of nuclear receptor-degradation inducers
- (2011) Yukihiro Itoh et al. BIOORGANIC & MEDICINAL CHEMISTRY
- Niphatenones, Glycerol Ethers from the Sponge Niphates digitalis Block Androgen Receptor Transcriptional Activity in Prostate Cancer Cells: Structure Elucidation, Synthesis, and Biological Activity
- (2011) Labros G. Meimetis et al. JOURNAL OF MEDICINAL CHEMISTRY
- Targeting the Binding Function 3 (BF3) Site of the Human Androgen Receptor through Virtual Screening.
- (2011) Nathan A. Lack et al. JOURNAL OF MEDICINAL CHEMISTRY
- New steroidal lactones as 5α-reductase inhibitors and antagonists for the androgen receptor
- (2011) Mariana Garrido et al. JOURNAL OF STEROID BIOCHEMISTRY AND MOLECULAR BIOLOGY
- Regression of Castrate-Recurrent Prostate Cancer by a Small-Molecule Inhibitor of the Amino-Terminus Domain of the Androgen Receptor
- (2010) Raymond J. Andersen et al. CANCER CELL
- Development of a Second-Generation Antiandrogen for Treatment of Advanced Prostate Cancer
- (2009) C. Tran et al. SCIENCE
- Targeted intracellular protein degradation induced by a small molecule: En route to chemical proteomics
- (2008) Ashley R. Schneekloth et al. BIOORGANIC & MEDICINAL CHEMISTRY LETTERS
- Sintokamides A to E, Chlorinated Peptides from the SpongeDysideasp. that Inhibit Transactivation of the N-Terminus of the Androgen Receptor in Prostate Cancer Cells
- (2008) Marianne D. Sadar et al. ORGANIC LETTERS
Discover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversationPublish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn More